This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Forest Labs Posts Earnings Miss

Forest Laboratories (FRX) missed earnings estimates for the second quarter of 2008 in light of a license fee but upped its full-year guidance Tuesday.

The drugmaker earned 71 cents a share, a 5% decrease from 75 cents a share in the year-ago quarter. Net income decreased 7% to $225.2 million from $241.1 million. Analysts surveyed by Thomson Financial were expecting 74 cents a share on revenue of $931 million.

Earnings were affected by a $70 million licensing charge (that equated to 15 cents a share net of tax) to Microbia for the right to co-develop and co-market constipation treatment linaclotide.

Research and development expenses increased 82% to $170.7 million during the quarter, including the $70 million licensing charge made in connection with the Microbia agreement.

Quarterly revenue increased 8.5% to $919 million from $847 million in the year-ago period. Sales of Lexapro for the treatment of depression and anxiety in adults totaled $559.1 million in the quarter, an increase of 7% from the year-ago period.

Sales of Namenda, a treatment for moderate and severe Alzheimer's disease, increased 24% to $192.9 million year over year. Forest said that product wholesalers held less inventory of both Lexapro and Namenda at the end of the September quarter, which negatively impacted combined sales by roughly $18 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
FRX $99.00 -0.77%
AAPL $127.60 2.28%
FB $83.09 2.87%
GOOG $535.38 2.16%
TSLA $205.27 -0.74%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs